Your browser doesn't support javascript.
loading
Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis.
Kraay, A N M; Steele, M K; Baker, J M; Hall, E W; Deshpande, A; Saidzosa, B F; Mukaratirwa, A; Boula, A; Mpabalwani, E M; Kiulia, N M; Tsolenyanu, E; Enweronu-Laryea, C; Abebe, A; Beyene, B; Tefera, M; Willilo, R; Batmunkh, N; Pastore, R; Mwenda, J M; Antoni, S; Cohen, A L; Pitzer, V E; Lopman, B A.
Afiliação
  • Kraay ANM; Department of Kinesiology and Community Health, University of Illinois, Champaign, IL, United States; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States. Electronic address: akraay@illinois.edu.
  • Steele MK; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
  • Baker JM; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
  • Hall EW; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
  • Deshpande A; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
  • Saidzosa BF; State Institution "Republican Center of Immunoprophylaxis" of Ministry of Health and Social Protection of Population of the Republic of Tajikistan, Dushanbe, Tajikistan.
  • Mukaratirwa A; Ministry of Health and Child Welfare, Zimbabwe.
  • Boula A; Mother & Child Hospital (MCH), Chantal Biya Foundation, Yaoundé, Cameroon.
  • Mpabalwani EM; University Teaching Hospital, Lusaka, Zambia.
  • Kiulia NM; Enteric Pathogens and Water Research Laboratory, Institute of Primate Research, Karen, Nairobi, Kenya.
  • Tsolenyanu E; Department of Paediatrics, Medical School of Lome, Togo; Ministry of Health, Togo.
  • Enweronu-Laryea C; Department of Pediatrics, University of Ghana Medical School, Accra, Ghana.
  • Abebe A; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Beyene B; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Tefera M; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Willilo R; RTI International, Dar es Salaam, Tanzania.
  • Batmunkh N; Expanded Programme on Immunisation, Regional Office for the Western Pacific, World Health Organization, Manila, Philippines.
  • Pastore R; Division of Country Health Programmes, Vaccine-preventable Diseases and Immunization (VPI), World Health Organization Regional Office for the Europe, Copenhagen, Denmark.
  • Mwenda JM; WHO Regional Office for Africa, Immunization and Vaccines Development, Brazzaville, Congo.
  • Antoni S; Department of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
  • Cohen AL; Department of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
  • Pitzer VE; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, United States.
  • Lopman BA; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Vaccine ; 40(46): 6631-6639, 2022 11 02.
Article em En | MEDLINE | ID: mdl-36210251
ABSTRACT
Rotavirus vaccination has been shown to reduce rotavirus burden in many countries, but the long-term magnitude of vaccine impacts is unclear, particularly in low-income countries. We use a transmission model to estimate the long-term impact of rotavirus vaccination on deaths and disability adjusted life years (DALYs) from 2006 to 2034 for 112 low- and middle-income countries. We also explore the predicted effectiveness of a one- vs two- dose series and the relative contribution of direct vs indirect effects to overall impacts. To validate the model, we compare predicted percent reductions in severe rotavirus cases with the percent reduction in rotavirus positivity among gastroenteritis hospital admissions for 10 countries with pre- and post-vaccine introduction data. We estimate that vaccination would reduce deaths from rotavirus by 49.1 % (95 % UI 46.6-54.3 %) by 2034 under realistic coverage scenarios, compared to a scenario without vaccination. Most of this benefit is due to direct benefit to vaccinated individuals (explaining 69-97 % of the overall impact), but indirect protection also appears to enhance impacts. We find that a one-dose schedule would only be about 57 % as effective as a two-dose schedule 12 years after vaccine introduction. Our model closely reproduced observed reductions in rotavirus positivity in the first few years after vaccine introduction in select countries. Rotavirus vaccination is likely to have a substantial impact on rotavirus gastroenteritis and its mortality burden. To sustain this benefit, the complete series of doses is needed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Rotavirus / Rotavirus / Vacinas contra Rotavirus / Gastroenterite Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Rotavirus / Rotavirus / Vacinas contra Rotavirus / Gastroenterite Idioma: En Ano de publicação: 2022 Tipo de documento: Article